Nutriband Inc. - Common Stock (NTRB)

ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQNTRB) NASDAQ:NTRBWNASDAQNTRBW)

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments

ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQNTRB)NASDAQ:NTRBWNASDAQNTRBW)

The approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica

The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia

ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQNTRB) NASDAQ: NTRBWNASDAQNTRBW)

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQNTRB) NASDAQ:NTRBWNASDAQNTRBW)

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.

AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch

ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQNTRB)NASDAQ:NTRBWNASDAQNTRBW)

Nutriband (NASDAQNTRB), a pharmaceutical company with a special focus on transdermal technologies, will be part of an upcoming live webinar hosted by RedChip Companies. Scheduled for October 17, 2024, at 4:15 p.m. ET, the exclusive event will feature Gareth Sheridan, Founder and CEO, and Serguei Melnik, Founder and President. Sheridan and Melnik will share insight into Nutriband’s current operations and upcoming milestones as well as field questions from listeners and investors.

ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQNTRB)NASDAQ:NTRBWNASDAQNTRBW)

Nutriband (NASDAQNTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more.

EQNX::TICKER_START (NASDAQNTRB),NASDAQ:NTRBWNASDAQNTRBW)(NYSE:TEVANYSETEVA,(NYSE:LLYNYSE),(NYSE:NVSNVS),(NASDAQAMRX) EQNX::TICKER_END

PALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent opioid formulations (ADFs) are designed to make it more difficult to abuse opioids by making them less attractive or rewarding, or by increasing the difficulty of manipulating them. ADFs can help reduce the risk of adverse effects associated with snorting or injecting opioids, and may also help prevent medication errors. Active companies in the industry include: Nutriband Inc. (NASDAQNTRB), Teva Pharmaceutical Industries Ltd. NYSE: TEVANYSETEVA)(NYSE: LLYNYSELLY, Novartis AG (NYSE: NVSNYSE), Amneal Pharmaceuticals, Inc. (NASDAQ: AMRXAMRX).

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology   Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products […]

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology

Nutriband (NASDAQNTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According to the company, AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch.

Last week, a group of women who experienced severe pain at a fertility clinic at Yale University after they received saline instead of a painkiller had their suits against the Ivy League school settled. This settlement comes after seven women sued the institution in 2021. Soon after, more patients filed lawsuits, which brought the number of plaintiffs to more than 150. Most of them claimed that because of their experience at the clinic, they suffered from post-traumatic stress disorder (PTSD).

Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patch

Nutriband (NASDAQNTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress on the development of AVERSA Fentanyl, with a target date of submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2025.

ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQNTRB)NASDAQ:NTRBWNASDAQNTRBW)

Nutriband (NASDAQNTRB), a developer of transdermal pharmaceutical products, is reporting its Q2 2024 financial results for the period ending July 31, 2024. According to the report, the company ended the quarter in a strong cash position, reinforcing its ability to advance the development of its lead product, AVERSA(TM) Fentanyl, with a New Drug Application (“NDA”) submission planned for the first half of 2025. The report showed Nutriband with cash reserves of $6.75 million, supporting the company’s ongoing development and commercialization efforts for AVERSA Fentanyl; total assets are valued at $13.63 million, with stockholders’ equity amounting to $12.5 million. The company noted that if AVERSA Fentanyl is approved, it could be the first and only abuse-deterrent transdermal patch available globally, with potential to see estimated annual sales of $80–$200 million.

ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQNTRB)NASDAQ:NTRBWNASDAQNTRBW)